Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vacucis Autovaccine for Chronic Oral Candidiasis
NCT05289375Not yet recruiting
- Sponsor
- Universidad de Santiago de Compostela
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, triple-blind trial of Vacucis in oral candidiasis (2 arms), sponsored by Universidad de Santiago de Compostela. Primary endpoints: Symptoms of candidiasis at 6 months, Oral signs of candidiasis at 6 months and 2 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Vacucis
03
Conditions
oral candidiasis
Beyond the preview
Go deeper on NCT05289375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289375.